Alveus Therapeutics has successfully launched with a $159.8 million Series A financing to develop innovative therapies for obesity and metabolic diseases, including advancing its lead program ALV-100.

Target Information

Alveus Therapeutics Inc. is a clinical-stage biotechnology firm focused on developing innovative therapies for obesity and metabolic diseases. Recently, Alveus launched with a substantial $159.8 million in Series A financing aimed at advancing its research and development pipeline. The lead program, ALV-100, is a bifunctional GIPR antagonist and GLP-1R agonist designed for effective weight management while enhancing the quality and sustainability of weight loss outcomes.

The company's pipeline also features a differentiated array of amylin-based compounds, including the highly selective amylin receptor agonist ALV-200, as well as oral small molecule therapies. This diverse portfolio positions Alveus at the forefront of tackling one of the most pressing healthcare challenges globally: obesity.

Industry Overview in the United States

The obesity crisis remains a significant public health issue in the United States, with approximately 42% of adults classified as obese, according to the CDC. The economic implications are profound, with healthcare cost